Genentech, a member of the Roche Group announced today positive data from the primary analysis of the Phase III HAVEN 1 study in adults and adolescents and interim analysis of the Phase III HAVEN 2 study in children evaluating once-weekly subcutaneous emicizumab prophylaxis (preventative) for the treatment of hemophilia A with inhibitors to factor VIII. Data from both studies will be presented on July 10 at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting in Berlin, Germany. To read the press release in full, click here.
